(Q30413201)

21 June 2017

Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines (English)

1 reference

21 June 2017

Friedemann Weber

2

0 references

author name string

Ralf D Hess

series ordinal

1

1 reference

21 June 2017

Keith Watson

series ordinal

3

1 reference

21 June 2017

Siegfried Schmitt

series ordinal

4

1 reference

21 June 2017

language of work or name

English

0 references

publication date

17 February 2012

1 reference

21 June 2017

1 reference

21 June 2017

30

1 reference

21 June 2017

2715-2727

1 reference

21 June 2017

17

1 reference

Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

An avian cell line designed for production of highly attenuated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Characteristics of a human cell line transformed by DNA from human adenovirus type 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Adenovirus type 5 early region 1B 156R protein promotes cell transformation independently of repression of p53-stimulated transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Cell-based influenza vaccines: progress to date.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Antiviral actions of interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Defective translational control facilitates vesicular stomatitis virus oncolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Reovirus therapy of tumors with activated Ras pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon Production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Virus replication in engineered human cells that do not respond to interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Viral tricks to grid-lock the type I interferon system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Viral suppression of the interferon system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Mumps virus Enders strain is sensitive to interferon (IFN) despite encoding a functional IFN antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

The cell-binding carboxyterminal undecapeptide of SV40 tumour antigen provides protective cell-dependent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

DNA-damage-inducible p53 activity in SV40-transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Simian virus 40 in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Short tandem repeat profiling provides an international reference standard for human cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

The tumorigenicity diversification in human embryonic kidney 293 cell line cultured in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Ras superfamily monomeric G proteins in carcinoma cell motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Assessing the tumorigenic phenotype of VERO cells in adult and newborn nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

AGAR SUSPENSION CULTURE FOR THE SELECTIVE ASSAY OF CELLS TRANSFORMED BY POLYOMA VIRUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Human muscle: a model for the study of human neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

HeLa cells 50 years on: the good, the bad and the ugly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Genomics: massively parallel sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Massively parallel sequencing, a new method for detecting adventitious agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Analysis of porcine circovirus type 1 detected in Rotarix vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Cryopreservation and banking of mammalian cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Introduction to workshop: adventitious viruses in biologics--detection and mitigation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

Vaccine quality--can a single standard be defined?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.015

10.1016/J.VACCINE.2012.02.015

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference